Skip to main content

Advertisement

SpringerLink
Log in

Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Aims

This study assessed the independent predictors of the hemoglobin A1c (HbA1c)-lowering effect of vildagliptin in Japanese patients with type 2 diabetes.

Materials and methods

The data of a total of 155 patients with type 2 diabetes who had been taking vildagliptin 50 or 100 mg once or twice daily for inadequate glycemic control for at least 12 weeks regardless of oral hypoglycemic agents (OHAs) were retrieved from medical records. Spearman’s rank correlation coefficient method was applied to determine the correlations between sets of two independent continuous variables. Multiple linear regression analysis was used to search for independent predictors of the reduction in HbA1c levels after 12 weeks of vildagliptin treatment (ΔHbA1c).

Results

Among all subjects, ΔHbA1c was positively correlated with baseline HbA1c (r = 0.549, P < 0.0001). Multiple linear regression analysis using baseline variables among all patients also revealed that the independent factors contributing to ΔHbA1c were prescribing method (drug naïve or add-on vs. switch from other OHAs; P < 0.0001) and baseline HbA1c (P < 0.0001), without being significantly influenced by body mass index, diabetes duration, or age.

Conclusions

Our analysis provides evidence that baseline HbA1c and prescribing method contribute to the HbA1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes. Long-term analysis of a larger population is warranted to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  CAS  PubMed  Google Scholar 

  2. Bando Y, Kanehara H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Invest. 2012;. doi:10.1111/j.2040-1124.2011.00156.x.

    Google Scholar 

  3. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–8.

    Article  CAS  PubMed  Google Scholar 

  4. Ahrén B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775–83.

    Article  PubMed  Google Scholar 

  5. Vanita RA, Robert RH, Jenny H, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34:1247–58.

    Article  Google Scholar 

  6. Tominaga M, Makino H, Yoshino G, et al. Japanese standard reference material for JDS Lot 2 haemoglobin A1c. I: comparison of Japan Diabetes Society-assigned values to those obtained by the Japanese and USA domestic standardization programmes and by the International Federation of Clinical Chemistry reference laboratories. Ann Clin Biochem. 2005;42:41–6.

    Article  CAS  PubMed  Google Scholar 

  7. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest. 2010;1:212–28.

    Article  Google Scholar 

  8. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39–40.

    Article  Google Scholar 

  9. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  CAS  PubMed  Google Scholar 

  10. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Am J Kidney Dis. 2003;41:1–12.

    Article  PubMed  Google Scholar 

  11. World Medical Association. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277:925–6.

    Article  Google Scholar 

  12. Okayama N, Imaeda K, Kato T, et al. Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: multicenter study. Diabetes Int. 2013;4:179–85.

    Article  Google Scholar 

  13. Chang JS, Shin J, Kim HS, et al. Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in Korean subjects with type 2 diabetes. Diabetes Metab J. 2013;37:72–80.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Senmaru T, Fukui M, Kobayashi K, et al. Dipeptidyl peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Invest. 2012;. doi:10.1111/j.2040-1124.2012.00220.x.

    Google Scholar 

  15. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.

    Article  CAS  PubMed  Google Scholar 

  16. Kim SA, Shim WH, Lee EH, Lee YM, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.

    Article  CAS  PubMed  Google Scholar 

  18. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–94.

    Article  CAS  PubMed  Google Scholar 

  19. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complicat. 2010;24:79–83.

    Article  PubMed  Google Scholar 

  20. Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus. Clin Drug Investig. 2011;31:665–74.

    Article  CAS  PubMed  Google Scholar 

  21. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors declare that they have no conflict of interest. This work was not supported by any grant.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503, Japan

    Yukihiro Bando, Masayuki Yamada, Keiko Aoki, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji, Daisyu Toya & Nobuyoshi Tanaka

Authors
  1. Yukihiro Bando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiko Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideo Kanehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Azusa Hisada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Okafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisyu Toya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuyoshi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukihiro Bando.

About this article

Cite this article

Bando, Y., Yamada, M., Aoki, K. et al. Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes. Diabetol Int 5, 229–233 (2014). https://doi.org/10.1007/s13340-014-0161-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-014-0161-3

Keywords

Search

Navigation